➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Johnson and Johnson
Boehringer Ingelheim
Colorcon

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

CYCRIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cycrin, and what generic alternatives are available?

Cycrin is a drug marketed by Esi and is included in three NDAs.

The generic ingredient in CYCRIN is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.

Summary for CYCRIN
Drug patent expirations by year for CYCRIN
Recent Clinical Trials for CYCRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
Women's Health Care Clinic, Torrance, CaliforniaPhase 4
Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranPhase 4

See all CYCRIN clinical trials

US Patents and Regulatory Information for CYCRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Esi CYCRIN medroxyprogesterone acetate TABLET;ORAL 081239-001 Oct 30, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
Esi CYCRIN medroxyprogesterone acetate TABLET;ORAL 081240-001 Oct 30, 1992 DISCN No No   Start Trial   Start Trial   Start Trial
Esi CYCRIN medroxyprogesterone acetate TABLET;ORAL 089386-001 Sep 9, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Moodys
Medtronic
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.